Abstract. Substantial preclinical evidence has indicated out a direct anti-proliferation effect of metformin on various solid tumors; however, further and more detailed exploration into its molecular mechanism remains to be performed. The present study aimed to investigate the effect of metformin on cell viability and its underlying mechanism, in the cultured human skin keratinocyte cell line, HaCaT. In addition, it aimed to clarify the role of the microRNA-21(miR-21)/phosphatase and tensin homolog (PTEN)/AKT serine/threonine kinase 1 (Akt) signaling pathway, which has been hypothesized to be involved in the molecular mechanism of this drug. Cell Counting Kit-8 assays were used to assess the impact of metformin on cell viability; reverse transcription-quantitative polymerase chain reaction was used to quantify the expression of miR-21; western blotting was used to monitor the expression level of PTEN and Akt proteins. In addition, miR-21 expression levels were artificially manipulated in HaCaT cells using a miR-21 inhibitor in order to observe the subsequent expression changes of miR-21 targets and alterations in cell viability. The results indicated that metformin suppressed HaCaT cell growth in a dose-and time-dependent manner (P<0.05). Metformin treatment downregulated miR-21 expression (t=-8.903, P<0.05). Following transfection with the miR-21 inhibitor, HaCaT cell growth was significantly slower than in the control groups (P<0.05). In addition, reduced miR-21 levels results in significantly increased PTEN protein expression levels and reduced Akt protein expression levels compared with control (P<0.05). Metformin was, therefore, concluded to inhibit HaCaT cell growth in a time-and dose-dependent manner, and the miR-21/PTEN/Akt signaling pathway may serve a crucial role in the molecular mechanism of metformin's effect on HaCaT cells. Therefore the present study presents an advanced insight into the potential inhibitory effect of metformin on tumor cells.
Introduction
HaCaT cells are an immortalized, non-tumorigenic cell line derived from keratinocytes of normal adult skin (1) . Pathologically excessive proliferation of these cells reportedly leads to various skin diseases, such as psoriatic lesions and various skin cancers (2) . Thus, HaCaT cells are extensively employed as an extrinsic cell instrument in anti-neoplastic medicine experiments (3) . Metformin, a biguanide insulin sensitizer widely prescribed to type 2 diabetes (4), has gained increasing focus due to its newly discovered anti-neoplastic capacity in a broad spectrum of malignant tumors, including prostate, pancreatic, ovarian and gastric cancers (5) (6) (7) (8) . However, the anti-growth ability of metformin seems to have tumor type dependence (9) and the mechanism whereby metformin affects various cancers is still not completely understood (10) .
MicroRNAs (miRNAs or miRs) are a class of small modulatory non-coding RNA molecules that can either bring about instability or translational efficiency repression through base-pairing to target mRNAs (11) , effectively resulting in the repression of molecules that take part in cell cycle processes including cell proliferation, differentiation and apoptosis (12) . miR-21 is reportedly overexpressed in the vast majority of solid neoplasms (13) . Among the target molecules of miR-21, phosphatase and tensin homolog (PTEN) and AKT serine/threonine kinase 1 (Akt) are of particular interest (14) . PTEN protein has been identified as a potent neoplasm inhibitor, while Akt is found positioned at the intersection of multiple signaling pathways, and is a verified sensing node that is upregulated in most tumors and can be suppressed by reversing the phosphorylation of the phosphoinositide 3-kinase (15) .
Therefore, the present study aimed to explore the in vitro proliferation inhibition effect of metformin on HaCaT cells and to investigate the mechanism which might be involved in the miR-21/PTEN/Akt signaling pathway. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). TRIzol ® reagent (cat. no. 15596-018; Invitrogen; Thermo Fisher Scientific, Inc.) was used for total RNA isolation. The amount and purity of RNA was assessed spectrophotometrically. Extracted RNA was reverse-transcribed into cDNA using a miRNA cDNA synthesis kit (cat. no. 203301; Universal cDNA Synthesis kit II; Takara Bio, Inc., Otsu, Japan) in accordance with the manufacturer's specification. qPCR was performed with the primers listed in Table I and ExiLENT SYBR ® Green master mix (cat. no. 203403; Takara Bio, Inc.), as outlined in Table II . An ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used. The amplification conditions of the PCR were as follows: 95˚C for 10 min, followed by 40 cycles at 95˚C for 10 sec and 60˚C for 1 min, the ramp-rate was 1.6˚C/sec. A total of three experimental repeats were performed. The 2 -ΔΔCq method was employed for quantitation, with miR-21 expression levels normalized to the U6 RNA control (16) .
Materials and methods

Cell
Western blotting analysis.
Following 48 h of treatment with 30 mM metformin, total protein was isolated from cells by incubation in radioimmunoprecipitation assay buffer (cat. no. P0013C; Beyotime Institute of Biotechnology, Haimen, China) containing 1 mM phenylmethane sulfonyl on ice for 30 min, followed by centrifugation at 13,690 x g, 4˚C for 30 min. Protein concentration was evaluated by bicinchoninic acid assay (cat. no. P0010; Beyotime Institute of Biotechnology). Proteins (50 µg per lane) were separated by 10% SDS-PAGE, then transferred to polyvinylidene difluoride membranes. Non-specific binding was blocked by incubation in 5% skimmed milk in Tris-buffered saline with 0.05% Tween-20 (TBST) buffer for 2 h at room temperature. Membranes were subsequently incubated at 4˚C overnight in the following primary antibodies: rabbit monoclonal anti-PTEN (1:1,000; cat. no. 9188; Cell Signaling Technology, Inc., Danvers, MA, USA), rabbit monoclonal anti-Akt1/2/3 (1:1,000; cat. no. 4685; Cell Signaling Technology, Inc.) or rabbit monoclonal anti-GAPDH (1:1,000; cat. no. 5174; Cell Signaling Technology, Inc.) as an internal reference. Membranes were then incubated with a horseradish peroxidase-conjugated secondary antibody (1:10,000; cat. no. 7074; Cell Signaling Technology, Inc.) at room temperature for 2 h. The membrane was developed using enhanced chemiluminescence (cat. no. 05-1327; EMD Millipore, Billerica, MA, USA) and scanned with an electrophoresis gel imaging analysis system (Tanon-5000R; Tanon Science & Technology Co., Ltd, Shanghai, China). Gray value of each band was quantified using ImageJ 1.46b (National Institutes of Health, Bethesda, MD, USA) relative to the GAPDH control.
Transfection with miR-21-inhibiting oligonucleotides.
HaCaT cells were divided into three groups: IN group, transfected miR-21-inhibitor (5'-TCA ACA TCA GTC TGA TAA GCT A-3'; Ambion; Thermo Fisher Scientific, Inc.); NC group, transfected 
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Results
Effect of metformin on HaCaT cell viability. CCK-8 assays demonstrated that increasing concentrations and durations of metformin treatment resulted in attenuation of
HaCaT cell viability (χ 2 =3.974; P<0.05; Fig. 1 ). This result indicated a time-and dosage-dependent inhibitory action of metformin on the viability of HaCaT cells.
Expression of miR-21 in HaCaT cells following metformin treatment.
Assessment of the effect of metformin treatment on the expression of miR-21 was a primary consideration. As demonstrated in Table III , miR-21 levels in the experimental and control groups were 1.14±0.18 and 2.67±0.23, respectively (P<0.05). Therefore, the levels of miR-21 expression were significantly reduced by metformin treatment.
Transfection results. To acquire a better understanding of the function of miR-21, a miR-21 inhibitor was transfected into HaCaT cells. RT-qPCR was then used to confirm the efficacy of miR-21 inhibition. Relative miR-21 quantitation data in the IN, NC and MOCK groups were 0.38±0.11, 1.09±0.17, and 1.03±0.09, respectively (Table IV and Fig. 2) . miR-21 expression was, therefore, significantly reduced in the IN group compared with the NC and MOCK groups (both P<0.05), indicating that the miR-21 inhibitor was effective at reducing miR-21 expression. Table IV and Fig. 3 ). By contrast, Akt protein expression was demonstrated to be significantly downregulated in cells in the IN group compared with the NC and MOCK groups (both P<0.05; Table IV and Fig. 3) .
Inhibition of miR-21 inhibits HaCaT cell viability.
Since miR-21 is overexpressed in most solid tumors (17) , miR-21 is hypothesized to promote tumor proliferation. Therefore, cell viability was examined by CCK-8 assay in cells with artificially lowered miR-21 levels. Cell growth was demonstrated to be downregulated in cells in the IN group compared with the NC and MOCK groups (Fig. 4) . This result indicates that reduced miR-21 expression inhibits HaCaT cell viability.
Discussion
To the best of the authors' knowledge, the present study is the first to demonstrate a duration-and dosage-dependent inhibitory effect of the anti-diabetic drug metformin on HaCaT cell viability. Furthermore, the miR-21 expression levels were observed to be significantly reduced following metformin treatment. Therefore, the present study conjectured that miR-21 serves a pivotal role in adjusting the proliferative activity of HaCaT cells. To investigate the suspected vital function of miR-21 in the anti-viability effect of metformin, miR-21 inhibitor transfection was used to artificially reduce miR-21 expression in HaCaT cells, which resulted in reduced growth compared with control cells.
Therefore, a tentative conclusion was drawn that miR-21 might be at the core of the basic mechanism by which metformin inhibits HaCaT cell growth. In order to further examine the function of miR-21, the effect of reduced miR-21 expression on 2 functional downstream targets of miR-21, PTEN and Akt, was examined (18, 19) . Significantly increased PTEN expression and decreased Akt expression was observed in cells transfected with the miR-21 inhibitor compared with cells transfected with the scrambled-sequence oligonucleotide or PBS (20) . Combined with the previously reported critical role of PTEN and Akt in regulating cellular biological procedures (21, 22) , an intricate modulatory network including miR-21 and PTEN/Akt was hypothesized to be involved in metformin's anti-proliferation effect. Yang et al (23) observed a high level of homology between the sequence of miR-21 and the 3'untranslated region (UTR) of PTEN mRNA, suggesting that miR-21 would bind to the 3'UTR of PTEN mRNA. This structural similarity between miR-21 and PTEN is a powerful mechanism explanation of miR-21's downregulatory effect on PTEN protein expression. A negative association has previously been demonstrated between PTEN and Akt activation (24) . However, some limitations and unsolved problems remain in the present study, such as the detailed mechanism of metformin's inhibitory effect on miR-21 and whether other signaling pathways are also involved in this effect. Further studies will examine these questions in the future.
Therefore, the present study concluded that metformin inhibits HaCaT cell viability via the miR-21/PTEN/Akt signaling pathway. The miR-21/PTEN/Akt signaling pathway may therefore be considered as a potential target to further investigate the molecular mechanism of metformin's action. This conclusion may consolidate certain theoretical foundations for associated research (25) and promote the application of metformin in skin cancer remedy (26) . Data are presented as the mean ± standard deviation and were statistically analyzed using the Mantel Haenszel χ 2 -test. Cell viability was significantly reduced in the IN group compared with MOCK and NC groups (P<0.05). miR, microRNA; MOCK, group mock-transfected with PBS; NC, group transfected with miR-21 inhibitor negative control; IN, group transfected miR-21-inhibitor; A 450 , absorbance at 450 nm.
